Log in to your Inderes Free account to see all free content on this page.
Create account

Cereno Scientific

6.05 SEK

+0.75 %

Less than 1K followers

CRNO B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

+0.75 %
-3.20 %
-8.89 %
-13.45 %
-23.32 %
-25.12 %
+599.42 %
+216.75 %
+0.65 %

Cereno Scientific is a biotechnology company. The company specializes in drug development for common and rare cardiovascular diseases. The lead drug candidate is being developed for the treatment of the rare disease pulmonary arterial hypertension, as well as for thrombotic indications. In particular, epigenetic modulation is used to develop treatments for needy patients with cardiovascular diseases. Cereno Scientific's headquarters are located in Mölndal.

Read more
Market cap
1.89B SEK
Turnover
2.49M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
27.5.
2026

Interim report Q1'26

17.6.
2026

General meeting '26

26.8.
2026

Interim report Q2'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Third party research

Cereno Scientific: Inflection points coming into view - Edison

Cereno Scientific’s FY25 results mark a strategically productive period, with multiple value inflection points coming into focus in FY26. With the Phase IIb start for lead asset CS1 expected in Q226, we anticipate a step-up in clinical activity and partnering...

Cereno Scientific
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.